Board of Directors

Mr. Garland is our Chairman of our board of directors and has served as a member of our board of directors since November 2022. He served as the Chief Executive Officer of PACT Pharma, Inc., an immuno-oncology company, from March 2021 to February 2023. Mr. Garland remains a member of PACT’s board of directors. He was formerly the Chief Executive Officer of Portola Pharmaceuticals, which was acquired by Alexion in 2020. At Portola, he led the company through the commercial launch of Andrexxa®, a novel reversal agent for factor Xa inhibitors. Before joining Portola, Mr. Garland held leadership roles at multiple pharmaceutical and biotechnology companies. At Relypsa, he served first as Chief Commercial Officer, then as President overseeing the U.S. commercial launch of Veltassa® for the treatment of hyperkalemia. Prior to Relypsa, Mr. Garland spent three years as Chief Commercial Officer at Exelixis, where he built the commercial organization for the company’s launch of cabozantinib in medullary thyroid cancer. He also spent nine years at Genentech, where he led the commercial franchises for two multibillion-dollar cancer therapies – Avastin® and Rituxan®. Mr. Garland is also a member of the board of directors of Day One Biopharmaceuticals and Calithera Biosciences, and formerly was a board member of Karyopharm Therapeutics. Mr. Garland received a Bachelor of Science degree from California Polytechnic State University, San Luis Obispo and an MBA from the Fuqua School of Business at Duke University.

Daniel J. Curran, M.D. has served as a member of our board of directors since July 2025 and also serves on the board of directors at Catalyst Pharmaceuticals (NASDAQ: CPRX) and Xilio Therapeutics (NASDAQ: XLO). Dr. Curran has over 25 years of experience in the pharmaceutical industry, including leadership roles in strategy, and business development. He currently serves as a Managing Partner at Mountainfield Venture Partners, LLC, and as Chief Executive Officer of Timberlyne Therapeutics, a clinical-stage biopharmaceutical company. Previously, Dr. Curran spent 15 years at Takeda Pharmaceuticals, most recently as Senior Vice President and Head of the Rare Genetics and Hematology unit. Before that, he served as Vice President, Corporate Development at Millennium Pharmaceuticals and held a business development role in the product planning and acquisition group at DuPont Merck Pharmaceuticals. Dr. Curran received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from The Wharton School of the University of Pennsylvania, and a B.S. in chemistry from King’s College.

Ms. Hemrajani has served as a member of our board of directors since April 2020. She currently serves as a director at MaxCyte and BioAge Labs. She has previously served as Chief Executive Officer and Director of Jiya Acquisition Corporation, a Special Purpose Acquisition Company, and President and Chief Executive Officer of Aravive, Inc., a clinical-stage biotechnology company, Chief Operating Officer and Chief Financial Officer of Arcus Biosciences, a biotechnology company, Chief Operating Officer of FLX Bio, Inc. (now RAPT Therapeutics, Inc.), a biotechnology company and Chief Financial Officer and Senior Vice President of Business and Financial Operations at 3-V Biosciences, Inc. (now Sagimet Biosciences, Inc.), a biotechnology company. Ms. Hemrajani was also Vice President, Head of Licensing and M&A at Onyx Pharmaceuticals (acquired by Amgen) and Vice President of Business Development at Exelixis. She started her career in healthcare investment banking at Credit Suisse First Boston and Lehman Brothers. She holds a Bachelor of Science degree in economics and computer science from the University of Michigan and an MBA from the Kellogg Graduate School of Management at Northwestern University.

Mr. Lettmann has served as our Chief Executive Officer since September 2023 and has been an investor/member of our board of directors since the company’s founding in 2015. He brings more than 20 years of experience as both a biotechnology operator and investor.

Prior to joining the Company, Mr. Lettmann was a Co-Founder and General Partner at Lightstone Ventures from 2012 to 2023, where he led investments in innovative life sciences companies. He also served as Chief Executive Officer of Promedior through its acquisition by Roche in 2020.

Mr. Lettmann has served on the boards of multiple public and private companies across the biotechnology and medical technology sectors, including ALX Oncology (NASDAQ: ALXO), Promedior (acquired by Roche), Ra Pharmaceuticals (acquired by UCB), Relievant (acquired by Boston Scientific), Tarsus (acquired by Integra Lifesciences), and Vapotherm (NASDAQ: VAPO).

He previously held investment roles as a General Partner at Morgenthaler Ventures as well as at Split Rock Partners and began his career in consulting at Accenture. Mr. Lettmann holds an M.B.A. with distinction from the University of Michigan Ross School of Business and a B.A. with honors from the University of Iowa.

Dr. Alan Sandler is currently the Chief Development Officer at Revolution Medicines. He serves as  a member of our board of directors and previously was Chief Medical Officer of ALX Oncology. Dr. Sandler joined our board of directors in 2024. He also currently serves as a member of the board of directors of Elevation Oncology, Inc., a member of the strategic advisory boards of TOLREMO therapeutics AG and N-Power Medicine, and as a member of  the clinical advisory board of Mythic Therapeutics. He served as Executive Vice President and Chief Medical Officer of Mirati Therapeutics, prior to and through its acquisition by Bristol Myers Squibb, from November 2022 to April 2024. Prior to joining Mirati Therapeutics, Dr. Sandler was the President, Head of Global Development, Oncology at Zai Lab Limited from December 2020 to October 2022. Prior to that, Dr. Sandler held roles of increasing responsibility at Genentech, and as a member of the Roche Group.

Dr. Takimoto has served as a member of our board of directors since January 2025. He currently serves as Global Chief Medical Officer at the START Center for Cancer Research. Dr. Takimoto has over 30 years of experience in oncology and pharmacology through a distinguished career across academia, industry and public service. He previously served as Chief Medical Officer at IGM Biosciences and Forty Seven, Inc., the latter through its acquisition by Gilead for $4.9 billion, and Senior Vice President of Oncology at Gilead Sciences, Inc. Prior to these positions, he held roles of increasing responsibility in oncology drug development at Janssen/Johnson & Johnson. Dr. Takimoto has held academic positions at the University of Texas Health Science Center at San Antonio, the National Cancer Institute and the Uniformed Services University of the Health Sciences, and he has served as a Commissioned Officer in the U.S. Public Health Service. Dr. Takimoto completed his internship and residency in internal medicine at the University of California, San Francisco, and a fellowship in oncology at the National Cancer Institute. He received a Bachelor of Science degree in chemistry from Stanford University, a Ph.D. in pharmacology from Yale University and an M.D. from Yale University School of Medicine.